Antihemophilic factor (recombinant), plasma/albumin free - Biologic Drug Details

Summary for antihemophilic factor (recombinant), plasma/albumin free

Tradenames:	1
High Confidence Patents:	0
Applicants:	2
BLAs:	2
Suppliers: see list	2

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for antihemophilic factor (recombinant), plasma/albumin free Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for antihemophilic factor (recombinant), plasma/albumin free Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Wyeth Pharmaceuticals Llc	XYNTHA, XYNTHA SOLOFUSE	antihemophilic factor (recombinant), plasma/albumin free	For Injection	125264		2014-01-21	DrugPatentWatch analysis and company disclosures
Wyeth Pharmaceuticals Llc	XYNTHA, XYNTHA SOLOFUSE	antihemophilic factor (recombinant), plasma/albumin free	For Injection	125264		2014-06-21	DrugPatentWatch analysis and company disclosures
Wyeth Pharmaceuticals Llc	XYNTHA, XYNTHA SOLOFUSE	antihemophilic factor (recombinant), plasma/albumin free	For Injection	125264		2015-09-22	DrugPatentWatch analysis and company disclosures
Wyeth Pharmaceuticals Llc	XYNTHA, XYNTHA SOLOFUSE	antihemophilic factor (recombinant), plasma/albumin free	For Injection	125264		2019-07-26	DrugPatentWatch analysis and company disclosures
Wyeth Pharmaceuticals Llc	XYNTHA, XYNTHA SOLOFUSE	antihemophilic factor (recombinant), plasma/albumin free	For Injection	125264		2019-10-25	DrugPatentWatch analysis and company disclosures
Wyeth Pharmaceuticals Llc	XYNTHA, XYNTHA SOLOFUSE	antihemophilic factor (recombinant), plasma/albumin free	For Injection	125264		2020-01-31	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for antihemophilic factor (recombinant), plasma/albumin free Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Wyeth Pharmaceuticals Llc	XYNTHA, XYNTHA SOLOFUSE	antihemophilic factor (recombinant), plasma/albumin free	For Injection	125264		2019-11-23	Patent claims search
Wyeth Pharmaceuticals Llc	XYNTHA, XYNTHA SOLOFUSE	antihemophilic factor (recombinant), plasma/albumin free	For Injection	125264		2019-08-17	Patent claims search
Wyeth Pharmaceuticals Llc	XYNTHA, XYNTHA SOLOFUSE	antihemophilic factor (recombinant), plasma/albumin free	For Injection	125264		2019-10-18	Patent claims search
Wyeth Pharmaceuticals Llc	XYNTHA, XYNTHA SOLOFUSE	antihemophilic factor (recombinant), plasma/albumin free	For Injection	125264		2034-04-23	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	ADVATE	antihemophilic factor (recombinant), plasma/albumin free method	For Injection	125063		2038-10-15	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	ADVATE	antihemophilic factor (recombinant), plasma/albumin free method	For Injection	125063		2019-11-23	Patent claims search

Market Dynamics and Financial Trajectory for Recombinant Antihemophilic Factor, Plasma/Albumin-Free

Last updated: February 20, 2026

What is the Current Market Size and Revenue?

The recombinant antihemophilic factor (rFVIII), plasma/albumin-free, targets hemophilia A management. The global hemophilia market was valued at approximately $11 billion in 2022 and expected to reach $17 billion by 2030, with a compound annual growth rate (CAGR) of 5.8%[1].

Recombinant formulations dominate the segment, with plasma/albumin-free variants gaining favor due to safety profiles. Estimates indicate that plasma/albumin-free rFVIII accounts for roughly 25-30% of the recombinant hemophilia A therapy market, translating to approximately $2.75-$3.3 billion in 2022.

What are the Drivers of Market Growth?

• Safety Profile: Plasma/albumin-free products eliminate risks associated with plasma-derived therapies, such as viral transmission.
• Technological Advancements: Improved manufacturing processes increase yield and reduce costs.
• Growing Patient Population: An increasing diagnosis rate of hemophilia A, particularly in emerging markets.
• Extended Half-Life (EHL) Products: Innovations in EHL rFVIII formulations increase treatment compliance and reduce infusion frequency, driving market adoption.
• Reimbursement and Policy Support: Enhanced healthcare coverage improves access, especially in North America and Europe.

What are the Market Challenges?

• Pricing Pressure: High costs of biologics constrain adoption, particularly in price-sensitive markets.
• Competition: Several biologics, including emicizumab (a monoclonal antibody for prophylaxis), challenge traditional rFVIII therapies.
• Manufacturing Complexity: Production of plasma/albumin-free rFVIII involves sophisticated bioprocessing, contributing to high costs.
• Regulatory Uncertainty: Variability in approval pathways across regions influences market entry timelines.

Who are Key Market Players?

Company	Product(s)	Market Position	Estimated Market Share (2022)
BioMarin	Ad أثناء_rate	Leaders	40%
Pfizer	ReFacto AF	Significant	25%
Bayer	Kovaltry	Growing	15%
Others	Various	Niche	20%

What are the Revenue Projections?

Based on current market dynamics, revenues from plasma/albumin-free rFVIII are projected to grow at a CAGR of approximately 7% from 2022 to 2030, driven by technological innovation and geographic expansion.

Year	Estimated Revenue (USD billion)
2022	3.0
2025	4.0
2030	5.4

What are Future Market Trends?

• Gene Therapy Competition: Improvements in gene therapy may reduce demand for repeated biologic treatments, impacting long-term revenue.
• Biosimilars Introduction: Entry of biosimilars could lower prices and expand access, reducing traditional biologic gross margins.
• Personalized Medicine: Customized dosing based on patient pharmacokinetics may improve outcomes, affecting market share.

What are Investment and R&D Opportunities?

• Enhancement of half-life extension technologies.
• Development of combination therapies.
• Focus on scalable, cost-effective manufacturing for emerging markets.
• Strategic alliances for patent protection and licensing.

Summary of Financial Key Indicators

Indicator	Value / Description
CAGR (2022-2030)	7% for plasma/albumin-free rFVIII revenues
Market Penetration	25-30% in recombinant hemophilia A biologics market
Price Range	USD 200,000 - USD 300,000 per year, per patient
Patent Expiry Dates	2025-2030 for key biologics, influencing market entry points

Key Takeaways

• The plasma/albumin-free recombinant antihemophilic factor market is expanding, driven by safety, technological advances, and increasing hemophilia A diagnosis.
• High costs and competition from newer therapies pose challenges.
• Revenues are expected to grow at approximately 7% CAGR through 2030.
• Market penetration remains limited but expanding, especially through innovations like extended half-life formulations.
• Investment in R&D is focused on improving pharmacokinetics, reducing costs, and expanding domestic access.

FAQs

1. How does plasma/albumin-free rFVIII differ from plasma-derived therapies?
Recombinant plasma/albumin-free rFVIII eliminates the risks of viral transmission inherent in plasma-derived products and offers consistent manufacturing quality.

2. What are the main regulatory hurdles?
Differences in approval standards across regions can delay market entry, but recent approvals focus on demonstrating biosimilarity and safety profiles.

3. How does pricing affect market adoption?
High costs limit access, especially in low-income countries; insurance coverage and reimbursement policies significantly influence uptake.

4. What role do biosimilars play?
Biosimilars can lower treatment costs and expand access, potentially capturing a significant market share once patents expire.

5. What upcoming innovations could disrupt this market?
Gene therapies for hemophilia A and advances in protein engineering that extend half-life are primary disruptive developments.

---

References

[1] IQVIA Institute. (2022). The Global Hemophilia Market Report 2022. Retrieved from https://www.iqvia.com